Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Vinorelbine | Navelbine | 4.8 Undesirable effects | Pulmonary embolism, Posterior reversible encephalopathy syndrome, Skin hyperpigmentation (serpentine supravenous hyperpigmentation) | Jan,2023 |
| Ciprofloxacin | Ciprobay | 4.5. Interactions with other medicinal products | Interactions with mycophenolate | Mar,2023 |
| Duvelisib | Copiktra | 4.5. Interactions with other medicinal products | Interactions with Cytochrome (CYP3A4) substrate | Mar,2023 |
| Sodium Zirconium Cyclosilicate | Lokelma | 4.5. Interactions with other medicinal products | Interactions with tacrolimus | Mar,2023 |
| Moxifloxacin | Avalox | 4.5. Interactions with other medicinal products | Interaction with agents containing bivalent or trivalent cation, charcoal, warfarin, nonsteroidal anti-inflammatory drugs , quinolone, and atenolol | Mar,2023 |
| Fluoxetine | Prozac | 4.5. Interactions with other medicinal products | Interaction with Benzodiazepines, Antipsychotics, Drug that is tightly bound to protein (e.g., Coumadin, Digitoxin) and Olanzapine. | Mar,2023 |